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996ABSTRACT
Background. In a liver transplant (LT) center, treatments with Prometheus were eval-
uated. The main outcome considered was 1 and 6 months survival.
Methods. During the study period, 74 patients underwent treatment with Prometheus; 64
were enrolled,with amean age of 51 13 years; 47men underwent 212 treatments (mean, 3.02
per patient). The parameters evaluated were age, sex, laboratorial (liver enzymes, ammonia)
and clinical (model for end-stage liver disease and Child-Turcotte-Pugh score) data.
Results. Death was veriﬁed in 23 patients (35.9%) during the hospitalization period, 20
patients (31.3%) were submitted to liver transplantation, and 21 were discharged. LT was
performed in 4 patients with acute liver failure (ALF, 23.7%), in 7 patients with acute on
chronic liver failure (AoCLF, 43.7%), and in 6 patients with liver disease after LT (30%).
Seven patients who underwent LT died (35%). In the multivariate analysis, older age
(P ¼ .015), higher international normalized ratio (INR) (P ¼ .019), and acute liver failure
(P ¼ .039) were independently associated with an adverse 1-month clinical outcome. On
the other hand, older age (P ¼ .011) and acute kidney injury (P ¼ .031) at presentation
were both related to worse 6-month outcome. For patients with ALF and AoCLF we
did not observe the same differences.
Conclusions. In this cohort, older age was the most important parameter deﬁning 1- and
6-month survival, although higher INR and presence of ALF were important for 1-month
survival and AKI for 6-month survival. No difference was observed between patients who
underwent LT or did not have LT.*Address correspondence to Paulo Marcelino, Hospital Curry
Cabral, Intensive Care Unit, Rua da Beneﬁcência, 8 1069-166
Lisbon, Portugal. E-mail: jp.azevedo.rodrigues@gmail.comLIVER failure is a critical illness characterized by jaun-dice, porto-systemic encephalopathy syndrome, coa-
gulopathy, and high mortality rates. The condition can be
precipitated in patients with or without chronic liver disease
and has several possible causes, including virus, toxins,
drugs, or metabolic stress [1,2].
Some patients recover spontaneously, but liver trans-
plantation (LT) achieves approximately 90% of cure rates
[1] and has become the therapy of choice for these patients.
Because of an organ shortage, effective therapies that allow
managing periods of decompensation or to bridge to LT
transplantation are still needed [3]. For this purpose, arti-
ﬁcial extracorporeal liver support systems have been
created, including the Molecular Adsorbents Recirculating
System (MARS) and Fractioned Plasma Separation and5
.org/10.1016/j.transproceed.2015.03.016Adsorption (FPSA e Prometheus), with the ability to
remove albumin-bound toxins.
These systems are promising in patients with acute-on-
chronic liver failure (AoCLF) and acute liver failure
(ALF), but there is lack of robust randomized, clinical trials
as far as outcomes and effective bridging to transplant are
concerned.
At the leading LT center in Portugal, a high number of
patients have been treated with both techniques, mostly
Prometheus, for the past 6 years. The aims of this study
were to assess the clinical experience with liver depurativeª 2015 by Elsevier Inc. All rights reserved.
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Table 1. Indications for Prometheus Treatment
Indication
Total (n ¼ 64)
n (%)
LIVER DEPURATIVE TECHNIQUES 997techniques and to highlight the groups of patients who
might beneﬁt the most from this treatment, considering
major clinical outcomes and survival.Acute liver failure 17 (26.6%)
Acute-on-chronic liver failure 16 (25%)
Post-transplant 20 (31.3%)
Rejection 6
No rejection mentioned 14
Cholestatic liver disease 16 (25%)
Hepatic encephalopathy syndrome 19 (29.7%)
Table 2. Laboratory Evaluation Before First Treatment of the




AST (U/L) 449 (886)
ALT (U/L) 427 (842)
GGT (U/L) 280 (1032)
ALP (U/L) 334 (424)
Total bilirubin (mg/dL) 27.3 (12.7)
Arterial ammonia (mg/dL) 81.2 (47.8)
INR 2.3 (1.9)
Abbreviations: AST, aspartate transaminase; ALT, alanine transaminase;
GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; INR, interna-
tional normalized ratio.MATERIALS AND METHODS
The study was retrospective, and data were collected from June
2008 to December 2012. All patients admitted to Curry Cabral
Hospital who were submitted to Prometheus were included.
Exclusion criteria were incomplete data and isolated incomplete
session.
The data collected consisted of demographic information (age, sex),
laboratorial data before the ﬁrst treatment (aspartate transaminase
[AST]; alanine transaminase [ALT]; gamma-glutamyltransferase
[GGT]; alkaline phosphatase [ALP]; international normalized ratio
[INR], ammonia; and total bilirubin, collected before and after Pro-
metheus treatment), and model for end-stage liver disease (MELD)
and Child-Turcotte-Pugh (CTP) score, also considered before the ﬁrst
treatment. Comorbidities were also taken into account, namely acute
kidney injury (AKI) and presence of any dialysis technique, presence
of mechanical ventilation, and presence of continuous infusion of
vasopressors, also before the ﬁrst treatment. Other data retrieved
included number of treatments per patient and technical complica-
tions, namely, hypotension (leading to further intervention such as
ﬂuid or vasopressor administration), ﬁlter coagulation, and other
complications recorded. Patientswere divided into 5 groups, according
to the indications for Prometheus treatment: ALF, AoCLF, post-
transplant liver disorders (rejection and with no mention of rejec-
tion), cholestatic liver diseases not included in the previous groups,
and hepatic encephalopathy syndrome (HES). ALF was deﬁned as an
INR 1.5 and any degree of mental alteration (HES) in a patient
without pre-existing cirrhosis and with an illness with less than 26-week
duration. AoCLF was deﬁned as 2 organ failures or a single kidney
failure in a patient with pre-existing cirrhosis. The need for treatment
was decided by a team that included LT surgeons, hepatologists, and
intensivists on a daily basis and considering the patient’s evolution.
This team was also was responsible for the decision on LT.
The major results considered were hospital discharge, trans-
plantation, or inpatient death, and 1-month and 6-month survival
rates were regarded as the major outcomes.
The Prometheus treatment was performed under an established
protocol and performed by trained professionals from Fresenius.
The protocol included a 6-hour treatment with the ﬁlters provided
by Fresenius, with the use of a continuous infusion of non-
fractionated heparin on a rhythm of 500 IU per hour. The need for
ultraﬁltration or dialysis was evaluated case by case.
Continuous variables are expressed as an average and standard
deviation. Categorical variables are presented as categories with
percentages. For comparative analysis, parametric (Student t test
for numeric variables, after conﬁrmation of the normal distribution
of data by the Kolmogorov-Smirnov test) and non-parametric tests
(c2 test or Fisher exact test for categorical variables) were used. To
establish dependence between variables, logistic regression analysis
was performed (backward-LR), with the use of variables that were
signiﬁcant on univariate analysis. A goodness-of-ﬁt test (Hosmer-
Lemeshow) was used to assess the ﬁt of the logistic regression
model. The variables identiﬁed in the univariate analysis were used
in the multivariate regression model. The dependent variables
considered were the survival at 1 and 6 months; the independent
variables were those evaluated (clinical, laboratorial, and
demographic variables). For the most signiﬁcant results, a receiver
operator characteristics (ROC) curve was generated, and the areaunder the curve was considered. A value of P < .05 was considered
statistically signiﬁcant. A comparative analysis between patients
with an adverse and favorable clinical outcome was performed in
the whole cohort as well as for patients with ALF and AoCLF.
Statistical analysis was performed with the use of SPSS 19.0 (Sta-
tistical Package for Social Sciences, SPSS, Inc., Chicago, Ill, United
States).
RESULTS
During the study period, 74 patients underwent treatment
with Prometheus, and 64 met the inclusion criteria, who
underwent 212 treatments (mean, 3.02 per patient; range,
1e11). This cohort presented a mean age of 51  13 years;
47 were men. The patient groups considered, regarding
indications to Prometheus, are presented in Table 1.
AKI was the most common comorbidity (n ¼ 27, 42%).
Dialysis was present 11 patients, mechanical ventilation in 6,
and vasopressor support in 4. Laboratorial data are pre-
sented in Table 2. Mean bilirubin level was 27.3  12.7,
which decreased 13.61  10.09 after Prometheus sessions.
The laboratorial and clinical data for the whole cohort is
presented in Table 2, and in Table 3 these data are pre-
sented separately for patients with ALF and AoCLF.
Death was veriﬁed in 23 patients (35.9%) during the
hospitalization period, 20 patients (31.3%) were submitted
to liver transplantation, and 21 were discharged. LT was
performed in 4 patients with ALF (23.7%), in 7 patients
with AoCLF (43.7%) and in 6 patients with liver disease
after LT (30%), and in other patients with other underlying
Table 3. Laboratory Evaluation Before First Treatment of





MELD (mean  SD) 27  9.2 37.1  7.7
CTP (mean  SD) 10.3  2.3 12.3  1.3
AST (U/L, mean  SD) 684  1258 196  177
ALT (U/L, mean  SD) 752  1352 194  220
GGT (U/L, mean  SD) 164  170 195  186
ALP (U/L, mean  SD) 267  205 185  114
Total bilirubin (mg/dL, mean  SD) 28.8  14.4 31.1  13.4
Arterial ammonia (mg/dL, mean  SD) 86  37 99  66
INR (mean  SD) 1.9  0.9 2.2  0.5
Abbreviations: AST, aspartate transaminase; ALT, alanine transaminase;
GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; INR, interna-
tional normalized ratio.
Table 4. Multivariate Analysis of Factors Associated With









Sex P ¼ .548 P ¼ .548




ALF P ¼ .025;
RC: 1.674
P ¼ .101
Post-transplant disorder P ¼ .213 P ¼ .656
HE P ¼ .304 P ¼ .645
AoCLF P ¼ .607 P ¼ .478
Total bilirubin
(pre-Prometheus)
P ¼ .454 P ¼ .471
Bilirubin fall
(post-Prometheus)
P ¼ .295; P ¼ .375
AKI P ¼ .861 P ¼ .013;
RC: 1.472
MELD P ¼ .269 P ¼ .026;
RC: 0.361




INR P ¼ .020;
RC 0.812
P ¼ .076
Ammonia P ¼ .123 P ¼ .141
ALT P ¼ .581 P ¼ .774
Hypotension (TC) P ¼ .480 P ¼ .211
Abbreviations: ALF, acute liver failure; HE, hepatic encephalopathy; AoCLF,
acute-on-chronic liver failure; AKI, acute kidney injury; MELD, model for
end-stage liver disease; CTP, Child-Turcotte-Pugh score; INR, international
normalized ratio; ALT, alanine transaminase; TC, technical complication; RC,
regression coefﬁcient.
Table 5. Multivariate Analysis of Factors Associated With





Age P ¼ .015; OR: 0.930
CI: 0.133; 0.013
P ¼ .011; OR: 0.929
CI: 0.132; 0.016
ALF P ¼ .039; OR: 0.166
CI: 3.538; e0.054
N/A
AKI N/A P ¼ .031; OR: 0.253
CI: 2.635; e0.097
INR P ¼ .019; OR: 0.378
CI: 1.802; e0.013
N/A
Abbreviations: ALF, acute liver failure; AKI, acute kidney injury; CI, conﬁdence
interval; INR, international normalized ratio; OR, odds ratio; N/A, not applicable.
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not reaching statistical signiﬁcance.
The most common complication was hypotension (n ¼ 21,
32.8%), with only a minority requiring initiation of vaso-
pressor support (n ¼ 6, 9.4%), or dose adjustment (n ¼ 3,
4.7%). Filter clotting was observed in 5 patients (7.8%).
Other complications included agitation (n ¼ 2), myoclonus
(n ¼ 1), hypertension (n ¼ 1), and nausea (n ¼ 1).
We were not able to record 1- and 6-month survival rates
from 8 patients because they were transferred to other
health care units. Of the remaining 56 patients, 33 (58.9%)
were alive at 1 month and 23 (35.9%) at the 6th month. By
univariate analysis, we observed that younger age, chole-
static liver disease, and lower CTP score were related to
improvement in 1- and 6-month survival rates. Higher INR
(P ¼ .020) and ALF (P ¼ .025) were negatively associated
with 1-month survival rate and the presence of AKI
(P ¼ .013), and higher MELD score (P ¼ .026) with worse
6-month outcome. These data are presented in Table 3. In
the multivariate analysis, older age (P ¼ .015), higher INR
(P ¼ .019), and ALF (P ¼ .039) were independently asso-
ciated with an adverse 1-month clinical outcome. On the
other hand, older age (P ¼ .011) and AKI (P ¼ .031) at
presentation were both related to worse 6-month outcome
(Table 4 and Table 5). The ROC curves for 1-month sur-
vival and INR and age and 6-month survival are presented
in Fig 1 and Fig 2, respectively. For patients with ALF and
AoCLF we did not observe the same differences.
DISCUSSION
In this study, a series of 212 treatments in 64 patients with
Prometheus, we observed that older age, higher INR, and
ALF were independently associated with an adverse
1-month clinical outcome. On the other hand, older age and
AKI at presentation were both related to worse 6-month
outcome. Nonetheless, these data concern all patients
enrolled, and we could not ﬁnd any distinction between
patients with ALF and AoCLF. We should stress that the
presented data are quite signiﬁcant regarding the number of
treatments and patients described. The signiﬁcant data thatwe describe are generally in accordance with the literature,
but, in speciﬁc patient groups, we could not ﬁnd those who
could beneﬁt the most with Prometheus. Only the general
data can be taken into account, and they deserve attention.
Regardless of the clinical condition, in this cohort, clinical
data were more important to the outcome than the speciﬁc
clinical condition, namely ALF or AoCLF.
The biological and gross laboratorial effects of liver
depurative techniques are well described. Smaller studies
proved the reduction of bilirubin [4e10], bile acids [11],
Fig 1. Receiver operator characteristics for 1-month survival
and INR (area under the curve, 0.739).
LIVER DEPURATIVE TECHNIQUES 999amino acids [12], and ammonia [9], with conﬂicting results
relating inﬂammation markers such as tumor necrosis
factor-alpha [10,13,14], and interleukin-6 [10,14]. MARS
was described in the improvement of hemodynamic
parameters such as mean arterial pressure in 2 randomized,Fig 2. Receiver operator characteristics for 6-month survival
and age (area under the curve, 0.698).controlled studies, although no clinical outcome could be
associated [7,15].
Larger clinical studies aiming at clinical outcomes are still
scarce. The studied biological effects, such as the observed
decrease in serum bilirubin, did not affect the 1-month or
6-month survival. Yet, in this cohort, hypotension and need
to increase vasopressor support, markers of systemic
inﬂammation, were not frequent.
One of the largest randomized, controlled clinical trials
thus far (RELIEF trial) showed that MARS reduces organ
dysfunction but has no impact on 28- and 90-day survival
without transplantation on patients with AoCLF [16].
Similarly, a prospective, randomized, controlled, parallel-
group multicenter trial reported no increase in the proba-
bility of survival of patients with AoCLF who were treated
with the Prometheus system when compared with standard
medical therapy (SMT); however, patients with a MELD
score greater than 30 treated with Prometheus had a sta-
tistically signiﬁcant better survival rate compared with that
of patients treated with SMT only [17]. Another random-
ized, controlled trial with 102 patients with ALF found no
statistical signiﬁcance in the 6-month survival rate between
SMT and MARS [18]. Presented data could not reproduce
the beneﬁt for higher MELD, but higher INR and the
presence of ALF inﬂuenced adversely the 1-month survival,
and older age was the sole parameter adversely affecting
both 1-month and 6-month survival. Nonetheless, in the
univariate analysis, both MELD and CTP could be related
to survival but lose statistical signiﬁcance in the multivariate
regression model.
A retrospective study that included 52 patients with ALF
treated with Prometheus showed 68% mortality in patients
who did not undergo LT; among the 28 patients who sur-
vived, 22 underwent LT. The authors suggested that Pro-
metheus should be reserved as a bridging therapy [6]. In the
studied cohort, we did not observe this fact, but patients
with AoCLF more frequently underwent LT (43.7%),
although the after-LT survival was not affected.
Another study comparing Prometheus with MARS in
patients with AoCLF also found that both led to improve-
ment and transplantation in 70% of the patients and that
the treatment appeared to be pointless in primary
nonfunctional and secondary liver failure cases [19]. Like-
wise, Oppert et al [4] observed global survival rate of 26% in
patients with ALF and AoCLF submitted to Prometheus,
with a higher survival rate among ALF patients. These data
could not be reproduced in the present study; we did not
ﬁnd any difference in 6-month survival for patients who
underwent LT and those who did not undergo LT.Study Limitations
In our data, we could not compare different liver depurative
techniques. The data only referred to Prometheus, and they
should be considered in that speciﬁc treatment. It is difﬁcult
to conduct properly randomized studies for comparison of
these most widely used techniques. Also, beside technical
1000 RODRIGUES, CASTRO, MOYA ET ALissues, relevant clinical outcomes or different biological
effects are yet to be described for these techniques.
CONCLUSIONS
In 64 patients who underwent 212 treatments with Prome-
theus, we found that older age was related to 1-month and
6-month survival. Higher INR (P ¼ .019) and acute liver
failure (P ¼ .039) were independently associated with an
adverse 1-month clinical, and AKI (P ¼ .031) at presentation
was related to worse 6-month outcome. For patients withALF
and AoCLF we did not observe the same differences. Severity
scores at presentation (MELD and CTP) were related to
1- and 6-month survival only in the univariate analysis. We
concluded that in the group of patients studied, age was the
most important parameter deﬁning 1- and 6-month survival.
LT was not related to a better survival in this cohort.
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